Abacavir (Ziagen) Research

DO. SEE. HEAR. KNOW. Visit TheBody.com's 2008 World AIDS Day Center >>

HIV/AIDS Basics & Prevention

Just Diagnosed

HIV Treatment

Living With HIV

AIDS Policy & Activism

HIV Around the World

Conference Coverage

Abacavir (Ziagen) Research

2006-2008 | 2005 | 2004 | 2003 | 2002 | 1998-2001

See also: Medication Side Effects | Drug Interactions

2006-2008

DHHS Adults and Adolescents Antiretroviral Treatment Guidelines Panel's Communication Regarding Abacavir (April 4, 2008)
To read PDF, click here
From AIDSinfo
Major Study Finds Red Flags When Using Epzicom as First-Line Therapy in People With High Viral Load (February 28, 2008)
Combination therapy that includes ABC/3TC found less effective in subgroup of antiretroviral-naive individuals.
From U.S. National Institute of Allergy and Infectious Diseases
Abacavir, Didanosine Associated With Higher Heart Attack Risk, D:A:D Study Finds (February 5, 2008)
An interview with Jens Lundgren, M.D.
In 15th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Increased Risk of Myocardial Infarction Associated With Abacavir and ddI (February 4, 2008)
From HIV i-Base
Position Statement by the D:A:D Steering Committee (February 4, 2008)
A discussion of the significance of a study examining the association between use of abacavir, didanosine and lamivudine and the risk of myocardial infarction.
To read PDF, click here
From D:A:D Steering Committee
Study Finds Heart Trouble With Ziagen and Videx (February 4, 2008)
From Project Inform
Abacavir Hypersensitivity Test Could Be Combined With Drug Resistance Test: Study (June 4, 2007)
From aidsmap.com
In Uganda, Three-NRTI Regimen Including Abacavir Is Better Tolerated Than Nevirapine-Based Regimen (February 7, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections

2005

Switching Due to Lipoatrophy: Tenofovir Bests Abacavir in Tolerability, Lipid Profile (December 16, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
Adverse Event Risk on Abacavir + Lamivudine Is Not Higher for Patients Coinfected With Hepatitis B and/or Hepatitis C (July 26, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
Low Incidence of Abacavir Hypersensitivity Reaction in Treatment-Naive and -Experienced Patients (July 26, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
Once-Daily Abacavir + Lamivudine + Tenofovir Fails in Naive Patients (April 2005)
In Expert Opinion on Investigational Drugs, from The Body PRO
Fixed-Dose Pill of Abacavir/Lamivudine Taken Once a Day Is Comparable to Twice-a-Day Abacavir + Lamivudine (February 25, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Sequencing and 2 of the Most Popular Backbone Regimens (February 25, 2005)
A comparison of resistance mutations with abacavir + lamivudine versus tenofovir + lamivudine.
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Abacavir Is Not Associated With the Metabolic Changes Seen in Patients Treated With Stavudine (February 24, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Severity and Rate of Abacavir Hypersensitivity Reactions Higher Than Previously Believed (February 23, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO

2004

Failure of Tenofovir/Abacavir/Lamivudine Combination Still Unexplained (July 13, 2004)
In The XV International AIDS Conference, from The Body PRO
Lamivudine/Abacavir Is an Effective Nucleoside Backbone in Combinations Other Than With Tenofovir (July 13, 2004)
Results suggest that the K65R mutation is behind the failure of this three-drug combination.
In The XV International AIDS Conference, from The Body PRO
Tenofovir and Abacavir Do Not Interact in Patients on Triple-Nucleoside Regimens (July 13, 2004)
In The XV International AIDS Conference, from The Body PRO
Abacavir Hypersensitivity Reaction Predicted by Genetic Test (March 26, 2004)
Research in Australia suggests the experimental test could drastically reduce hypersensitivity reactions, but is prone to false positives.
In AIDS Treatment News, from AIDS Treatment News
Virologic Failure Analyzed in a Trial of Once-Daily Versus Twice-Daily Abacavir/3TC Regimens (February 9, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Improvement in Lipoatrophy Associated With Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus-Infected Patients Switched from Stavudine to Abacavir or Zidovudine: The Results of the TARHEEL Study (January 15, 2004)
When people who had developed lipoatrohpy while taking d4T (stavudine, Zerit) switched to abacavir (Ziagen) or AZT (zidovudine, Retrovir), their condition improved.
In Clinical Infectious Diseases
Update on the Safety and Efficacy of Abacavir (July 14, 2004)
In The XV International AIDS Conference, from The Body PRO

2003

Reasons for Early Abacavir Discontinuation in HIV-Infected Patients (November 2003)
Abstract of a study in the Annals of Pharmacotherapy.
In IAPAC Monthly, from International Association of Physicians in AIDS Care
Clinical Risk Factors for Hypersensitivity Reactions to Abacavir: Side Effects of Antiretroviral Therapy (September 17, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
Can Abacavir Be Given Once-a-Day? (September 16, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
Interim Analysis of Failure of Tenofovir/Abacavir/3TC Regimen (September 16, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
Emergence of Resistance-Associated Mutations Over 96 Weeks in Patients Initiating ABC/3TC + d4T, EFV or APV/r (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
Abacavir Not Inferior to AZT in Treatment-Naive Patients (September 14, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients With Human Immunodeficiency Virus Infection (September 11, 2003)
In The New England Journal of Medicine
Viread, Epivir and Ziagen Combination -- Failure in Naive Patients With a Once-Daily Regimen (September/October 2003)
Daniel S. Berger, M.D., chief investigator in study ESS30009, examines what went wrong.
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
Early Virologic Non-Response in Patients With HIV Infection Treated With Lamivudine, Abacavir and Tenofovir (July 25, 2003)
"Dear Healthcare Provider" letter from GlaxoSmithKline.
From U.S. Food and Drug Administration
Abacavir/3TC/Tenofovir Combination Fails in Treatment-Naive Patients (July 14, 2003)
Analysis by Benjamin Young, M.D., Ph.D.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
Abacavir/3TC/Tenofovir Combination Failure in Treatment-Naive Patients (July 14, 2003)
Analysis by Timothy Wilkin, M.D.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
Addition of Abacavir Does Not Appreciably Enhance the Antiviral Potency of a Standard Triple-Therapy Regimen (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
Combivir + Abacavir Better Tolerated and More Potent Than Combivir + Nelfinavir (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
Comparison of Once-Daily FTC Vs. Twice-Daily Abacavir in a Regimen for Drug-Naive Patients (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
Substituting AZT or Abacavir for d4T in Patients With Lipoatrophy (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
Abacavir Arm Stopped in Clinical Trial (April 4, 2003)
In AIDS Treatment News, from AIDS Treatment News
Improvements in Body Fat and Mitochondrial DNA Levels Are Accompanied by Decreased Adipose Tissue Cell Apoptosis After Replacement of Stavudine Therapy With Either Abacavir or Zidovudine (February 13, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO

2002

Secondary Syphilis and Abacavir Hypersensitivity Reaction (October 26, 2002)
In 40th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
Lack of Recurrence of Symptomatic and Asymptomatic Hyperlactatemia When Stavudine Is Replaced by Either Abacavir or Zidovudine: 48-Week Data (September 24, 2002)
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO
Genotypic and Virtual Phenotypic Correlates of Virologic Response to Abacavir-Based Therapy in the ZORRO Trial (ESS40009) (July 11, 2002)
In The XIV International AIDS Conference, from The Body PRO
Abacavir Substitution for Nucleoside Analogs in Patients With HIV Lipoatrophy (July 10, 2002)
In Journal of the American Medical Association
Abacavir Use in HIV-Positive Pregnant Women (July 10, 2002)
In The XIV International AIDS Conference, from The Body PRO
Simplification of Protease Inhibitor-Based Highly Active Antiretroviral Regimens With Abacavir Improves Hyperlipidemia and Maintains Viral Suppression in HIV-1-Infected Adults (ESS40003) (July 10, 2002)
In The XIV International AIDS Conference, from The Body PRO
Switching Protease Inhibitors to Nevirapine, Efavirenz or Abacavir: A Randomized, Multicenter, Open-Label, Simplification Trial (July 10, 2002)
In The XIV International AIDS Conference, from The Body PRO
Durability and Tolerability of the Triple NRTI Regimen Abacavir/Zidovudine/Lamivudine Based on Therapy Changes in Antiretroviral Therapy-Naive Patients in the Frankfurt HIV Cohort (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO
Phenotypic and Genotypic Profiles Predict Week 24 Responses to an Abacavir-Containing Salvage Regimen (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO
Resistance Profiles at Baseline and Following Virologic Failure for Subjects Randomized to Receive Abacavir/Efavirenz/Didanosine +/-; Hydroxyurea After Failing Initial NRTI +/- PI Therapy (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO
Successful Intensification of Antiretroviral Therapy With Abacavir in Clinical Practice (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO
Using Abacavir to Avoid Lipid Problems (March 20, 2002)
Report from the 9th Annual Retrovirus Conference.
From Canadian AIDS Treatment Information Exchange
HLA-B57 and TNF-Alpha Variants Associated With Hypersensitivity Reactions to Abacavir Among HIV-1-Positive Subjects (February 27, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
The Presence of HLA-B*5701, -DRB1*0701, and -DQ3 Is Highly Predictive of Hypersensitivity to the HIV Reverse Transcriptase Inhibitor Abacavir (February 27, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Switching Stavudine or Zidovudine to Abacavir for HIV Lipoatrophy: A Randomized, Controlled, Open-Label, Multicentre, 24-Week Study (February 25, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO

1998-2001

Diverse Effects of NRTI-Associated Mutations on Resistance to Abacavir, Stavudine and Zidovudine in the ZORRO Trial (December 18, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
Virologic Response to Abacavir/Efavirenz/ddI + Hydroxyurea in Subjects Failing Initial NRTI + PI Therapy (NZTA4008 Study) (December 18, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
Simplification of Protease Inhibitor-Containing HAART Regimen With Abacavir Maintains Viral Suppression and Favorable Adherence in HIV-1 Infected Adults (October 27, 2001)
In 39th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
The Compact Quad, Combivir/Abacavir/Efavirenz -- Preliminary 48-Week Results (October 27, 2001)
In 39th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
Prospective Study of Hyperlipidemia in ART-Naive Subjects Taking Abacavir/Combivir/Nelfinavir, or Lamivudine/Stavudine/NFV (GSK Protocol ESS40002) (October 26, 2001)
In 3rd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO
Abacavir/Combivir Is Comparable to Indinavir/Combivir in HIV-1 Infected Antiretroviral Therapy Naive Adults: Preliminary Results of a 48-Week Open-Label Study (CNA3014) (July 10, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
Risk Factor Analysis of Hypersensitivity Reactions to Abacavir: Retrospective Analysis of 25 Clinical Trials (July 10, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
Short-Term Immuno-Suppressive Therapy With Prednisolone in HIV-1-Infected Patients Receiving Abacavir With or Without Nevirapine (July 10, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
A Randomized Open Label Study to Investigate Abacavir and Lamivudine as Once-Daily Components of a Triple-Combination Regimen (July 9, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
Comparison of Symptoms of Influenza A Infection With Abacavir-Associated Hypersensitivity Reaction (February 7, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Epidemiological Risk Factors and Immunological Mechanisms of Hypersensitivity Reactions to Abacavir (February 7, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Intracellular Carbovir Triphosphate Levels Among Patients Taking Abacavir Once Daily (February 7, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Determination of a Clinically Relevant Phenotypic Resistance "Cutoff" for Abacavir Using the PhenoSense Assay (February 5, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Phosphorylation of Zidovudine, Stavudine, and Abacavir in Peripheral Blood Mononuclear Cells in Treatment-Naive and Treatment-Experienced Patients (February 5, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Anti-HIV Drugs Update (October 2000)
In Project Inform Perspective, from Project Inform
Abacavir vs. Indinavir in Therapy-Naive People (CNA3014) (August 17, 2000)
In STEP Ezine, from Seattle Treatment Education Project
PROTRA Study: To Evaluate the Safety and Efficacy of Abacavir and Efavirenz When Substituted for a PI in HIV-1-Infected Subjects Treated With Two NRTIs and a PI With Plasma HIV-RNA Levels Below the Limit of Assay Quantification (July 11, 2000)
In The XIII International AIDS Conference, from The Body PRO
The Multiple Nucleoside Analogue Resistance Mutations Confer Cross-Resistance to Abacavir (February 1, 1999)
In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Antiretroviral Effects of Therapy Combining Abacavir With HIV Protease Inhibitors (February 2, 1998)
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.